Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Vivos Expanding its Revenue Generating Initiatives
As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of
Year Over Year Improvement Due to Successful Cost Cutting Initiatives